MAIA

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

Retrieved on: 
Friday, April 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Lung cancer, Trial of the century, MAIA, FDA, DNA, Clinical trial, News, NSCLC, Pharmaceutical industry

Participants should refer to the final program agendas for up-to-date information.

Key Points: 
  • Participants should refer to the final program agendas for up-to-date information.
  • MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses.
  • Recent news from MAIA’s THIO-101 trial includes:
    Early completion of enrollment; topline data expected in second half of 2024; ( press release, February 22, 2024 )
    Strong response rate of 38% in third-line treatment efficacy data; ( press release, March 6, 2024 ).
  • Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; ( MAIA Shareholder Letter 2024 ).

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Yee, Believer, MAIA, Cancer, Science

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M.
  • made individual purchases of 69,282 and 6,928 shares of common stock, respectively, as part of the Company’s recent private placement of common stock and warrants.
  • “I believe MAIA is well positioned to create a great deal of value for its shareholders over time,” added Mr. Guerrero.
  • Over the course of his career, Mr. Luput has successfully completed multiple multi-million dollar real estate partnerships, consolidations, mergers, and acquisitions.

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

Retrieved on: 
Friday, March 22, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, University, MAIA, Sale, Textbook, Cancer, Economics

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
  • On March 11, 2024, MAIA entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company’s common stock, and warrants to purchase up to 2,043,587 shares of the Company’s common stock, at a price per share of $1.17.
  • The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company.
  • Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages.

Synapsia and Smart TV Brands Merge Horizons: Unveiling MAIA, the Future of AI-Powered Television Experience

Retrieved on: 
Tuesday, March 12, 2024
Freedom, MAIA, Artificial intelligence, AI, Maestro, Web3, Life, Classification, Ecosystem, Spatial, Heart, Smart TV, Natural language, Partnership, Television

Synapsia is redefining the digital realm with its cutting-edge approach to the Web3 ecosystem, offering transformative, interoperable solutions that span various platforms.

Key Points: 
  • Synapsia is redefining the digital realm with its cutting-edge approach to the Web3 ecosystem, offering transformative, interoperable solutions that span various platforms.
  • This technology enhances Natural Language Understanding, classification, and knowledge-building, leading to the generation of high-quality data and improved user interactions.
  • Moreover, Synapsia is rolling out cutting-edge, real-time Data Intelligence services that support a wide range of formats, redefining how users interact and experience digital content.
  • To sum up, the collaboration between Synapsia and the smart TV sector is setting the stage for a future where advanced AI and pioneering Smart TV technology converge, paving the way for unprecedented user experiences and asserting MAIA's dominant position in the evolution of AI.

Insurtech Boston Announces Speaker Lineup

Retrieved on: 
Wednesday, March 6, 2024
Marketing, MAIA, Hosta, House, House of Blues, Insurance, Machine learning, Management

Milwaukee, WI., March 06, 2024 (GLOBE NEWSWIRE) -- Ivans today announced its lineup for Insurtech Boston 2024, taking place May 7 at House of Blues.

Key Points: 
  • Milwaukee, WI., March 06, 2024 (GLOBE NEWSWIRE) -- Ivans today announced its lineup for Insurtech Boston 2024, taking place May 7 at House of Blues.
  • Following last year’s action-packed event, Insurtech Boston is back with a day full of networking and sessions with the industry’s leading digital innovators and industry groups, including Insurance Nerds, Trusted Choice, and Massachusetts Association of Insurance Agents (MAIA).
  • The event will also host a live podcast recording of The Insurance Technology Podcast.
  • Kate Terry, co-founder and CEO of Surround Insurance, Boston-based startup offers lifestyle-based insurance for driving, renting, and freelancing.

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, MAIA, Gilead Sciences, Medicine, ASH, ASCO, SAB, FDA, Drug development, AbbVie, European Hematology Association, Mantle cell lymphoma, Pleasure, Kite Pharma, Hematology, EHA, University, Society, University of Bern, Patient, NK, Pharmacyclics, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

Retrieved on: 
Thursday, March 7, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, NSCLC, Cancer, Laguna Niguel, California, MAIA, News, Conference, Lung cancer, The Ritz-Carlton Hotel Company, Clinical trial, Trial of the century, DNA, Pharmaceutical industry

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 in Dana Point, California.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 in Dana Point, California.
  • will host one-on-one meetings with institutional investors and analysts on Monday, March 18th and Tuesday, March 19th.
  • MAIA plans to pursue the FDA’s accelerated approval program for THIO.
  • Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; ( MAIA Shareholder Letter 2024 ).

MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Children, Biotechnology, Health, Pharmaceutical, Oncology, Research, Family, Hospitals, Consumer, Science, Clinical Trials, Cancer, Central nervous system, Radiation, Immune system, MAIA, Ohio State University, Cell proliferation, Nationwide Children's Hospital, Nationwide, Hospital, Brain, AACR, Survival rate, Prognosis, CNS, Associate, Survival, Immunotherapy, DIPG

The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.

Key Points: 
  • The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.
  • The study explored the combination of THIO and ionizing radiation (IR) treatments to induce direct anticancer effects and stimulate anti-tumor immunity in diffuse intrinsic pontine glioma (DIPG).
  • DIPG, a very difficult-to-treat and high-risk childhood cancer, is a central nervous system (CNS) tumor that forms in the brainstem.
  • Scientists from Nationwide Children’s Hospital and MAIA have shown that THIO synergistically sensitizes DIPG cells to ionizing radiation (IR), significantly decreasing cell proliferation.

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Retrieved on: 
Friday, November 17, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Sale, Regulation D, Research, NYSE, Security (finance), Form, MAIA, Cancer, 3rd Floor

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the shares of common stock issued in the registered direct offering was made only by means of a prospectus supplement that forms a part of the registration statement.
  • A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov .

MAIA Biotechnology Announces $4 Million Registered Direct Offering

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Sale, Regulation D, Research, NYSE, Security (finance), Form, MAIA, Cancer, 3rd Floor

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share in a registered direct offering.

Key Points: 
  • MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share in a registered direct offering.
  • The offering is expected to close on or about November 17, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to MAIA from the offering are expected to be approximately $4 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the shares of common stock to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement.